CNSTOCK News (Shanghai Securities News) — On the evening of January 6, Jointown Pharmaceutical Group (600998.SH) announced that Huiyu Yuanhe (Hainan) Pharmaceutical Co., Ltd., a subsidiary of the company's unit Beijing Jingfeng Pharmaceutical Group, has received the "Drug Registration Certificate" for Bupivacaine Hydrochloride Injection approved and issued by the National Medical Products Administration (NMPA).
According to the announcement, Bupivacaine Hydrochloride Injection is a long-acting amide local anesthetic primarily used for local infiltration anesthesia, peripheral nerve blocks, and spinal blocks. The drug is listed in the National Medical Insurance Category A and the National Essential Medicine List. Data from Minenet shows that in 2024, the sales of Bupivacaine Hydrochloride Injection across China's three major terminals and six major markets exceeded 200 million RMB.
As of the date of the announcement, Huiyu Yuanhe has invested approximately 4.66 million RMB (unaudited) in research and development for this drug.
The announcement stated that the approval of Bupivacaine Hydrochloride Injection as a Category 3 chemical drug signifies that it is deemed to have passed the Consistency Evaluation for Quality and Efficacy of Generic Drugs. Under relevant national policies, drug varieties that pass the consistency evaluation will receive greater support in areas such as medical insurance payment and procurement by medical institutions.
Jointown remarked that the approval of this drug is conducive to expanding the company's market share and further enriching its injectable product pipeline. This move is expected to enhance the company's competitiveness in the injectable market and support the continuous and steady development of its self-produced pharmaceutical industrial business.

https://finance.eastmoney.com/a/202601073610798225.html